Summary
Regeneron Pharmaceuticals, Inc. reported a slight decrease in total revenues to $3,145.0 million for the first quarter of 2024, down from $3,162.1 million in the same period last year. This was primarily driven by a decrease in EYLEA net product sales in the U.S., offset by strong growth in Dupixent, Libtayo, and Praluent. Net income saw a decline to $722.0 million from $817.8 million, resulting in diluted EPS of $6.27 compared to $7.17 year-over-year. Despite the revenue dip, the company demonstrated solid operational cash flow generation. Investment in research and development increased significantly, reflecting continued commitment to pipeline expansion. The company also continues its share repurchase program, with $1.233 billion remaining authorization as of March 31, 2024, and authorized an additional $3.0 billion in April 2024.
Financial Highlights
46 data points| Revenue | $3.15B |
| R&D Expenses | $1.25B |
| SG&A Expenses | $689.00M |
| Operating Expenses | $2.39B |
| Operating Income | $751.40M |
| Interest Expense | $16.10M |
| Net Income | $722.00M |
| EPS (Basic) | $6.70 |
| EPS (Diluted) | $6.27 |
| Shares Outstanding (Basic) | 107.80M |
| Shares Outstanding (Diluted) | 115.10M |
Key Highlights
- 1Total revenues for Q1 2024 were $3,145.0 million, a slight decrease from $3,162.1 million in Q1 2023.
- 2Net income decreased to $722.0 million ($6.27 diluted EPS) from $817.8 million ($7.17 diluted EPS) in the prior year period.
- 3Net product sales increased by $93.3 million to $1,761.3 million, driven by strong performance in Libtayo (+45%) and Praluent (+38%), partially offset by a decline in EYLEA U.S. sales.
- 4Collaboration revenue was $1,383.7 million, down from $1,494.1 million, primarily due to lower Roche collaboration revenue (REGEN-COV) and a slight decrease in Bayer collaboration revenue, while Sanofi collaboration revenue increased.
- 5Research and development expenses increased by $147.2 million to $1,248.4 million, reflecting ongoing investment in pipeline advancement.
- 6The company generated $1,512.5 million in cash from operating activities, showcasing strong cash flow generation.
- 7Shareholder returns remain a focus, with $298.0 million in common stock repurchases during the quarter, and $1.233 billion remaining under an authorized repurchase program as of March 31, 2024.